Furthermore, PIM inhibition decreases CLL cell chemotaxis in a mechanism that involves decreased CXCR4 surface expression and inhibition of CXCR4‐induced mTOR pathway. This evidence concerns the gene MTOR and B-cell chronic lymphocytic leukemia.